Results of the PRESTOCON preclinical trial are in
Results of the PRESTOCON preclinical trial are in
The results of the PRESTOCON preclinical trial have demonstrated that Panax ginseng and Gingko biloba extracts have a well-documented safety profile and are well tolerated for the treatment of moderate-to-severe disease.
In addition, the trial provided useful insights into the application of Panax ginseng (G115) and Gingko biloba (GK501) as novel and natural therapeutic intervention for the treatment of cognitive-related diseases.
These findings support the idea that the combination may become a valid and safe therapeutic intervention in the treatment of neurological disorders.
Robert Hendriks MD
Chief Executive Officer, SFI Health
Learn
Research is important, and we want to share it. Our articles distill the complex research and offer expert analysis on the microbiome, brain health and wellbeing.
Young-onset dementia: rising incidence or better recognition?
Young-onset dementia is changing fast - discover what’s driving it.
Read more
Why resolutions fail by February: the neuroscience of habit loops, cognitive load and motivation fatigue
The neuroscience behind failed resolutions - and the evidence-based habits that actually last.
Read more
Promising results from a preliminary study evaluating the impact of long-chain polyunsaturated fatty acids on reading and writing skills in...
New study links omega-3 fatty acids to improved reading and writing skills in children through key neurocognitive processes.
Read more